VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,000 shares of the biotechnology company’s stock, valued at approximately $517,000.

Several other hedge funds have also added to or reduced their stakes in ARWR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after acquiring an additional 2,774,933 shares during the period. Marshall Wace LLP lifted its stake in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the last quarter. Norges Bank purchased a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $30,414,000. Invesco Ltd. grew its holdings in Arrowhead Pharmaceuticals by 142.8% during the second quarter. Invesco Ltd. now owns 762,665 shares of the biotechnology company’s stock valued at $12,050,000 after purchasing an additional 448,585 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Health Canada issued a Notice of Compliance for REDEMPLO™ (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), giving Arrowhead its first approved indication in Canada and creating a near-term commercial foothold and revenue opportunity. Health Canada Approval
• Positive Sentiment: Interim Phase 1/2a data for ARO‑INHBE and ARO‑ALK7 showed meaningful weight loss and reductions in visceral and total fat and liver measures in obese patients with diabetes — results that de‑risk Arrowhead’s obesity/metabolic franchise and broaden mid/long‑term upside beyond rare disease assets. Interim Clinical Data
• Positive Sentiment: Analyst sentiment has been improving: several research shops have raised price targets and maintained Buy/Outperform ratings in recent months, supporting higher expectations for stock valuation if approvals and clinical progress continue. Analyst Coverage Summary
• Neutral Sentiment: Institutional ownership remains high (~62.6%), which can amplify moves in either direction; liquidity and analyst coverage are robust, increasing sensitivity to news flow. Institutional Ownership
• Negative Sentiment: A cluster of insider sales has been disclosed recently — including CEO Christopher Anzalone selling 13,187 shares (and a series of prior large disposals) — which may prompt investor caution about insiders monetizing gains even if filings show retained large equity positions. Insider Sales Alert
• Negative Sentiment: Additional insider transactions include sizable sales by James C. Hamilton and COO Patrick O’Brien (SEC forms filed), which could weigh on near‑term sentiment even if sales are for diversification or tax planning. SEC Filing (Hamilton)

Insider Activity

In other news, Director Michael S. Perry sold 16,250 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director directly owned 115,240 shares in the company, valued at $7,033,097.20. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider James C. Hamilton sold 40,164 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the sale, the insider owned 171,958 shares in the company, valued at $10,852,269.38. This trade represents a 18.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 510,836 shares of company stock worth $33,603,060 in the last three months. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

ARWR has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright upped their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Royal Bank Of Canada boosted their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Finally, Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.89.

Arrowhead Pharmaceuticals Stock Down 5.8%

ARWR stock opened at $63.88 on Tuesday. The stock has a 50-day simple moving average of $55.20 and a two-hundred day simple moving average of $35.35. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $72.36. The firm has a market capitalization of $8.68 billion, a PE ratio of -798.40 and a beta of 1.21. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.